Ascorbic acid and gastrointestinal cancer.
A literature review was made to critically evaluate the ability of ascorbic acid to modulate the incidence of gastrointestinal cancer. A comparison of preclinical, clinical, and epidemiological studies indicated that evidence for ascorbic acid as an inhibitor of carcinogenesis is stronger with regard to gastric cancer and weaker with regard to esophageal and colon/rectal cancer. Insufficient evidence currently exists regarding the oral cavity and the use of ascorbic acid in precancerous conditions such as polyposis and leukoplakia.
Cohen
M
M
Scientific Information Services, Hoffmann-La Roche, Nutley, NJ 07110, USA.
Bhagavan
H N
HN
D000818:Animals; D016588:Anticarcinogenic Agents; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000517:prevention & control; D004938:Esophageal Neoplasms / Q000517:prevention & control; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D012004:Rectal Neoplasms / Q000517:prevention & control; D013274:Stomach Neoplasms / Q000517:prevention & control
D016588:Anticarcinogenic Agents; D001205:Ascorbic Acid